T1	CHEM 1 12	Miltefosina
#1	AnnotatorNotes T1	C0068006; miltefosine; Organic Chemical · Pharmacologic Substance
T2	CHEM 20 44	antimoniato de meglumina
#2	AnnotatorNotes T2	C1096768; meglumine antimoniate; Organic Chemical · Pharmacologic Substance
T3	PROC 51 62	tratamiento
#3	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	DISO 69 89	leishmaniasis mucosa
#4	AnnotatorNotes T4	C1328252; Mucocutaneous leishmaniasis; Disease or Syndrome
T5	PROC 94 118	tratamiento convencional
#5	AnnotatorNotes T5	C2945704; Conventional Treatment; Therapeutic or Preventive Procedure
T6	DISO 127 153	leishmaniasis tegumentaria
T7	CHEM 160 184	antimoniato de meglumina
#6	AnnotatorNotes T7	C1096768; meglumine antimoniate; Organic Chemical · Pharmacologic Substance
T8	DISO 246 262	efectos adversos
#7	AnnotatorNotes T8	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T9	PROC 420 445	ensayo clínico de fase II
#8	AnnotatorNotes T9	C0282460; Phase 2 Clinical Trials; Research Activity
T10	DISO 463 483	leishmaniasis mucosa
#9	AnnotatorNotes T10	C1328252; Mucocutaneous leishmaniasis; Disease or Syndrome
T11	PROC 498 517	comparó la eficacia
#10	AnnotatorNotes T11	C1707887; Efficacy Study; Research Activity
T12	CHEM 521 532	miltefosina
#11	AnnotatorNotes T12	C0068006; miltefosine; Organic Chemical · Pharmacologic Substance
T13	PROC 679 708	videofibroscopia nasofaríngea
T14	PROC 594 604	evaluación
#12	AnnotatorNotes T14	C1261322; Evaluation procedure; Health Care Activity
T15	PROC 627 639	tratamientos
#13	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	PROC 663 674	seguimiento
#14	AnnotatorNotes T16	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T17	DISO 747 763	lesiones mucosas
#15	AnnotatorNotes T17	C2673622; Mucosal lesions; Finding
T18	PROC 797 808	seguimiento
#16	AnnotatorNotes T18	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T19	CHEM 926 937	miltefosina
#17	AnnotatorNotes T19	C0068006; miltefosine; Organic Chemical · Pharmacologic Substance
T20	PROC 947 960	quimioterapia
#18	AnnotatorNotes T20	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure + C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T21	CHEM 1031 1042	miltefosina
#19	AnnotatorNotes T21	C0068006; miltefosine; Organic Chemical · Pharmacologic Substance
T22	ANAT 141 153	tegumentaria
#20	AnnotatorNotes T22	C0037267; Integumentary system; Body System
T23	PROC 286 311	administración parenteral
#21	AnnotatorNotes T23	C0678823; parenteral administration; Therapeutic or Preventive Procedure
T24	CHEM 568 588	compuesto antimonial
T25	Route 301 311	parenteral
#22	AnnotatorNotes T25	C1518896; Parenteral Route of Drug Administration; Functional Concept
T26	LIVB 449 458	pacientes
#23	AnnotatorNotes T26	C0030705; Patients; Patient or Disabled Group
T27	Route 537 545	vía oral
#24	AnnotatorNotes T27	C1527415; Oral Route of Drug administration; Functional Concept
T28	LIVB 816 825	pacientes
#25	AnnotatorNotes T28	C0030705; Patients; Patient or Disabled Group
T30	Date 852 857	ahora
T31	LIVB 904 913	pacientes
#26	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T29	Neg_cue 828 830	No
T32	CONC 858 869	diferencias
#27	AnnotatorNotes T32	C1705241; Delta (difference); Quantitative Concept
A1	Assertion T32 Negated
R1	Negation Arg1:T29 Arg2:T32	
R2	Overlap Arg1:T32 Arg2:T30	
T33	Spec_cue 1043 1049	podría
T34	CONC 1065 1076	alternativa
A2	Assertion T34 Speculated
#28	AnnotatorNotes T34	C1523987; Alternative; Qualitative Concept
T35	Quantifier_or_Qualifier 1089 1097	efectiva
A3	Assertion T35 Speculated
#29	AnnotatorNotes T35	C1280519; Effectiveness; Qualitative Concept
T36	Quantifier_or_Qualifier 1100 1106	segura
A4	Assertion T36 Speculated
R3	Speculation Arg1:T33 Arg2:T34	
R4	Speculation Arg1:T33 Arg2:T35	
R5	Speculation Arg1:T33 Arg2:T36	
R6	Used_for Arg1:T2 Arg2:T3	
R7	Used_for Arg1:T1 Arg2:T3	
R8	Location_of Arg1:T22 Arg2:T6	
R9	Used_for Arg1:T7 Arg2:T5	
T37	Observation 203 220	falla terapéutica
#30	AnnotatorNotes T37	C0162643; treatment failure; Finding
R11	Before Arg1:T7 Arg2:T37	
R12	Causes Arg1:T7 Arg2:T8	
T38	Quantifier_or_Qualifier 263 269	graves
#31	AnnotatorNotes T38	C1547227; Severe - Severity of Illness Code; Intellectual Product
R10	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T38	
R13	Used_for Arg1:T7 Arg2:T23	
R14	Has_Route_or_Mode Arg1:T7 Arg2:T25	
R15	Experiences Arg1:T26 Arg2:T10	
R16	Has_Route_or_Mode Arg1:T12 Arg2:T27	
R17	Experiences Arg1:T26 Arg2:T12	
R18	Experiences Arg1:T26 Arg2:T24	
T39	Observation 611 639	respuesta a los tratamientos
#32	AnnotatorNotes T39	C1319171; Medication response; Finding
R19	Overlap Arg1:T39 Arg2:T15	
T40	CONC 726 743	score de gravedad
#33	AnnotatorNotes T40	C0457451; Severity score; Quantitative Concept
R23	Used_for Arg1:T40 Arg2:T14	
R30	Experiences Arg1:T28 Arg2:T14	
R31	Experiences Arg1:T28 Arg2:T39	
R32	Experiences Arg1:T28 Arg2:T15	
R33	Experiences Arg1:T28 Arg2:T13	
R34	Experiences Arg1:T28 Arg2:T17	
R35	Experiences Arg1:T31 Arg2:T19	
R36	Experiences Arg1:T31 Arg2:T20	
T41	Observation 914 921	curados
#34	AnnotatorNotes T41	C0184780; Disease condition determination, cured; Finding
R37	Causes Arg1:T19 Arg2:T41	
R38	Causes Arg1:T20 Arg2:T41	
R39	Experiences Arg1:T31 Arg2:T41	
R40	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T34	
R41	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T35	
R42	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T36	
T42	Quantifier_or_Qualifier 870 884	significativas
A5	Assertion T42 Negated
#35	AnnotatorNotes T42	C0750502; Significant; Idea or Concept
R43	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T42	
R44	Negation Arg1:T29 Arg2:T42	
#36	AnnotatorNotes T30	C1948052; Now (temporal qualifier); Temporal Concept
#37	AnnotatorNotes T24	C0303099; Antimony compound (substance); Inorganic Chemical
A6	Experiencer T26 Patient
A7	Experiencer T28 Patient
A8	Experiencer T31 Patient
